Mice were injected subcutaneously (s.c) with OVA (0.5 mg/mouse) (day 0) combined with Imiquimod cream (Meda-Aldara™; topical application; 2.5 mg/mouse; days 0-2) or poly(I:C) (Amersham; 50 μg/mouse; s.c.; day 0). When using peptide TRP2(180–188), mice received 50 μg of peptide (s.c.; days 0–2) and topical Imiquimod as above. Additionally, the mice received i.p. injection of anti-IL-10R (clone 1B1.3A; 500 μg), anti-PD-1 (clone RMP1–14; 200 μg) or the corresponding isotype control antibodies (all from BioXcell) the day of immunization, with or without 30 mg/kg of RXDX-106 (oral route) administered from day 0 to 5. In some experiments, C57BL6/J mice were injected i.v. with 5 x 106 CD4 cells obtained from OT-II mice after purification by negative selection (Miltenyi Biotec) and immunized 24 h later. Mice were sacrificed at day 2 for MER, AXL and IL-10 analyses and at day 7 for ELISPOT assays, and splenocytes or tumor-infiltrating cells were obtained for immune characterization.
Isotype control antibody
Manufactured by BioXCell
Sourced in United States
An isotype control antibody is a laboratory reagent used to assess the specificity of target-specific antibodies. It is an antibody of the same isotype as the target-specific antibody, but it recognizes an irrelevant antigen. Isotype control antibodies provide a critical control for flow cytometry, immunohistochemistry, and other immunoassays to ensure the specificity of target-specific antibody binding.
Automatically generated - may contain errors
Lab products found in correlation
Anti il 10, by BioXCell (2 mentions)
Savant speedvac, by Thermo Fisher Scientific (2 mentions)
Matrigel, by Corning (2 mentions)
αpd 1 antibody, by BioXCell (2 mentions)
Anti human mouse il 5 monoclonal antibody trfk5 clone, by R&D Systems (2 mentions)
Sb328437, by Bio-Techne (2 mentions)
Negative selection, by Miltenyi Biotec (1 mentions)
Poly 1 c, by Cytiva (1 mentions)
Anti pd 1 clone rmp1 14, by BioXCell (1 mentions)
Anti il 10r clone 1b1.3a, by BioXCell (1 mentions)
Il 17a, by BioXCell (1 mentions)
Ctla 4, by BioXCell (1 mentions)
Il 4 clone 11b11, by BioXCell (1 mentions)
Anti α4, by BioXCell (1 mentions)
Anti lfa 1, by BioXCell (1 mentions)
α cd8 clone 2, by BioXCell (1 mentions)
Anti cd8 clone rpa t8, by BD (1 mentions)
Lipopolysaccharides (lps), by Merck Group (1 mentions)
Adenosine, by Merck Group (1 mentions)
Anti pd 1 be0146, by BioXCell (1 mentions)
27 protocols using isotype control antibody
1
Evaluating Immunotherapeutic Interventions in Melanoma
2
Sporadic CRC Immunotherapy Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For sporadic CRC model (Cdx2-Cre+/ApcF/WT mice), IL-17A, CTLA-4, and PD-1 neutralizing antibodies or isotype control antibodies (Bio X Cell) were i.p. injected at a dose of 100 μg per mouse every 3 days until sacrifice.
For the tamoxifen inducible model of tumorigenesis, antibodies (100 μg per mouse, every 3 days) were injected 1 day after the dose of tamoxifen until sacrifice.
For the tamoxifen inducible model of tumorigenesis, antibodies (100 μg per mouse, every 3 days) were injected 1 day after the dose of tamoxifen until sacrifice.
3
Modulating Corneal Inflammation with Cytokine Antibodies
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
As previously described, we used monoclonal antibodies against mouse interleukin-4 (IL-4; clone 11B11; 5 μg/g/dose; Bio-X-cell, West Lebanon, NH, USA) or rat antibody against mouse IL-13 (clone 38213; 5 μg/g; R&D Systems, Minneapolis, MN, USA), and administered them intraperitoneally [16 (link)]. Controls were treated with similar doses of isotype control antibodies (Bio-X-cell). Mice were treated with IL-4 monoclonal antibody (mAb), IL-13mAb, or isotype control antibodies 24 hours prior to corneal surgery, then weekly (IL-4mAb) or every 4 days (IL-13mAb) for 2 weeks after surgery.
4
Treg Depletion Impacts Mucosal Defense
5
Treg Depletion Impacts Mucosal Defense
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
To determine the impact of increased Treg responses induced by microbiota from helminth-infected host on mucosal defense against Citrobacter, the microbiota recipient mice were injected intraperitoneally (i.p.) with anti-IL-10 (BioXCell, West Lebanon, NH) and anti-CD25 (BioXCell) or isotype control antibodies (BioXCell) every other day starting one day before and continuing for 9 days after C. rodentium infection. CD4+CD25+ cell depletion was confirmed by FACS.
6
Anti-α4 and Anti-LFA-1 Antibody Treatment in SLC-/- Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
This treatment has been described previously (2 (link), 3 (link)). Briefly, SLC−/− mice were injected on days 0, or 0 and 5, i.p. with anti-α4 (clone: M17/4; 100 μg) and/or anti-LFA-1 (clone: PS/2; 100 μg) or isotype control antibodies (BioXcell, USA), and sacrificed after 5 h or at day 14. At the time of sacrifice, blood, and spleens were collected.
7
Depletion of CD8+ and γδ T cells
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Anti-γδ TCR (clone UC7-13D5) was purchased from Biolegend. αCD8 (clone 2.43) and isotype control antibodies were purchased from BioXCell. Antibodies were given intraperitoneally to deplete relevant cells every 3 days until the end of the tumor treatment regimen. Doses/mouse: 250 µg αCD8 and 75 µg anti-γδ TCR. Confirmation of depletion efficiency is shown in online supplemental figures S1 and S2 .
8
Immune Checkpoint Blockade Assay Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
NECA, adenosine and LPS were purchased from Sigma-Aldrich. Oxaliplatin, CPI-444, AZD4635 and AB928 were purchased from MedChemExpress, DZD2269 was designed and synthesized by Dizal Pharmaceuticals. All the compounds were dissolved in DMSO to prepare a 10 mM stock solution and stored in a nitrogen cabinet before use. Anti-PD-1 (BE0146) and Isotype control antibodies were purchased from Bioxcell. Anti-mouse CD45 PE (clone 30-F11), anti-mouse CD4 PerCP (clone RM4-5), anti-mouse CD8a FITC (clone 53 − 6.7), anti-CD45 FITC (clone HI30), anti-human CD8 PE (clone RPA-T8), anti-human CD4 FITC (clone PRA-T4), anti-CD14 PE (clone M5E2), anti-HLA-DR APC-H7 (clone G155-178), anti-CD83 APC (clone HB15e), anti-CD4 (clone, RPA-T4) and anti-CD8 (clone RPA-T8) were purchased from BD Bioscience. Anti-pCREBSer133 Alexa Fluor 647 (clone 87G3) and anti-mouse CD8 (clone D4W2Z) were purchased from Cell Signaling Technology. Anti-human CD3 antibody (clone OKT3) and anti-human CD28 antibody (clone CD28.2) were purchased from eBioscience. Anti-mouse CD3 antibody (clone 145-2C11) and anti-mouse CD28 antibody (clone E18) were purchased from BioLegend. Anti-mouse CD4 (EPR19514) was purchased from Abcam.
9
Malaria Immune Checkpoint Blockade
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For the PDL-1/LAG3/CTLA-4-blocking experiment with in vivo stimulation at day 14, malaria-infected and control mice were treated i.p. with a 300μL cocktail containing 400 μg of anti-mouse PDL-1, 400 μg of anti-mouse LAG3 and 400 μg of anti-mouse CTLA-4, or isotype control antibodies (BioXcell, West Lebanon, NH) 7, 9, 11, and 13 days after malaria infection. For the experiment in which mice were challenged at day 14 after malaria infection, an additional injection of 260μg of antibody was given at day 15. For the IL-10 blocking experiment, a total of 600 μg of rat anti-mouse IL-10 immunoglobulin G1 (IgG1) kappa (eBioscience, San Diego, CA) or isotype control was given i.p. in the following manner; 300 μg on day 13, 200 μg on day 14, and 100 μg on day 15.
10
Anti-H3 Antibody Treatment in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Mice were treated i.p. with H3 Ab or Isotype control antibody (Bioxcell, Lebanon, NH, USA) (50 µg/mouse) two times per week. Treatments were initiated at 6 weeks of age, and the experiment was terminated at 11 weeks of age.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!